VTI Raises $3.5 Million Series B Financing

As part of this first tranche of Series B financing, VTI will focus on expanding its manufacturing and inventory capacities concurrent with its sales team. “We believe VTI’s modular technology has the potential to significantly disrupt the current spine market,” said Matt Kyle, CEO at Vertebral Technologies, Inc. “We are excited about the opportunity that this financing gives VTI to grow market awareness and position.” VTI’s proprietary, intra-operative assembly™ technology gives surgeons the ability to implant a large, biomechanically stable implant through a smaller access channel than with currently available lumbar fusion products. The device is implanted one module at a time, through a small access channel. The fullyassembled implant provides a larger surface area and an anatomical lock, resulting in less likelihood of subsidence or migration.

EB-5 is an investor visa program administered by the United States Citizenship and Immigration Services (USCIS) to stimulate the U.S. economy through the creation of jobs and capital investments in U.S. companies by foreign investors. VTI noted that it continues to await approval by the USCIS of the final I-526 Petitions for this project, with another $3.5 million in escrow as of Monday. For more information about the EB-5 immigrant investor program, go to http://www.uscis.gov/eb-5/.

ABOUT VERTEBRAL TECHNOLOGIES, INC.

Vertebral Technologies, Inc. (VTI) is a privately held company based in Minnetonka, MN, USA. VTI is dedicated to the design, development, manufacturing and marketing of medical devices to address painful conditions of the spine through less-invasive surgical approaches. Founded in 2005, VTI’s products utilize its unique modular-assembly technology to deliver solutions optimized for both surgeons and their patients. VTI has sold over 7,000 InterFuse modular interbody fusion devices worldwide to-date.

For more information visit, http://vtispine.com or contact Brian Thron at marketing(at)vti-spine(dot)com or + 1.877-912-5401

< Return to All Press Releases